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Abstract
Esophageal adenocarcinoma (EAC) has become the dominant type of esophageal cancer in
United States. The 5-year survival rate of EAC is below 20% and most patients present with
locally advanced or widespread metastatic disease, where current treatment is largely inef-
fective. Therefore, new therapeutic approaches are urgently needed. Improvement of EAC
patient outcome requires well-characterized animal models in which to evaluate novel thera-
peutics. In this study we aimed to establish a peritoneal dissemination xenograft mouse
model of EAC that would support survival outcome analyses. To find the best candidate cell
line from 7 human EAC cell lines of different origin named ESO26, OE33, ESO51, SK-GT-2,
OE19, OACM5.1C and Flo-1 were injected intraperitoneally/subcutaneously into SCID mice.
The peritoneal/xenograft tumor formation and mouse survival were compared among differ-
ent groups. All cell lines injected subcutaneously formed tumors within 3 months at variable
rates. All cell lines except OACM5.1C formed intraperitoneal tumors within 3 months at vari-
able rates. Median animal survival with peritoneal dissemination was 108 days for ESO26
cells (5X106), 65 days for OE33 cells (5X106), 88 days for ESO51 cells (5X106), 76 days for
SK-GT-2 cells (5X106), 55 days for OE19 cells (5X106), 45 days for OE19 cells (10X106) and
82 days for Flo-1 cells (5X106). Interestingly, only in the OE19 model all mice (7/7 for 5X106
and 5/5 for10X106) developed bloody ascites with liver metastasis after intraperitoneal injec-
tion. The median survival time of these animals was the shortest (45 days for 10X106 cells).
In addition, median survival was significantly increased after paclitaxel treatment compared
with the control group (57 days versus 45 days, p = 0.0034) along with a significant decrease
of the relative subcutaneous tumor volume (p = 0.00011). Thus peritoneal dissemination
mouse xenograft model for survival outcome assessment after intraperitoneal injection of
OE19 cells will be very useful for the evaluation of cancer therapeutics.
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Introduction
Esophageal adenocarcinoma (EAC) has become the dominant type of esophageal cancer in
United States. EAC now represents the fastest growing cancer in the western world. The inci-
dence of EAC is increasing while the incidence of esophageal squamous cell remains unchanged
[1–6]. Despite recent advances in surgical and radiation technique as well as in systemic medical
treatment, prognosis of EAC remains poor [7–9]. The overall 5 year survival rate of EAC is
below 20% and most patients present with locally advanced or widespread metastatic disease,
where current treatment is largely ineffective [10, 11]. Therefore, new therapeutic approaches
are urgently needed. Thus the poor survival rate of EAC patients warrants further evaluation of
other anticancer drugs that block potential pathways of EAC progression.
Researchers often use a mouse model of esophageal cancer to evaluate these novel therapies
prior to clinical protocol treatment [12–18]. Subcutaneous xenograft models are very com-
monly used for testing the efficacy of anticancer agents in many cancers including EAC. But
mice subcutaneous EAC models only represent local tumor growth and do not provide any
information about a survival benefit for a particular anticancer regimen, which is very crucial
for experimental treatment efficacy. In addition, it has been observed that anticancer agents
may well inhibit subcutaneous tumor growth without effecting overall animal survival [19].
One of the major obstacles in developing novel therapies for EAC has been the lack of an ani-
mal survival model for testing these anticancer pharmacotherapeutics. Thus improvement of
esophageal adenocarcinoma patient outcome requires well-characterized animal survival mod-
els in which to evaluate novel therapeutics.
In this report, we present for the first time the successful establishment of a peritoneal dis-
semination mouse xenograft model for survival outcome analysis with intraperitoneal injec-
tion of human EAC cell lines.
Materials and methods
Ethics statement
All mouse experiments used in this study were carried out in accordance with the standards
and guidelines of the Institutional Animal Care and Use Committee (IACUC) at the Univer-
sity of Notre Dame and confirmed to NIH guidelines. All animal researches used in this study
were approved by the University of Notre Dame IACUC under protocol 15-08-263. At the end
of experiments mice were euthanized by CO2 exposure followed by cervical dislocation
according to University of Notre Dame IACUC-approved procedures.
Cell lines culture and reagents
Human esophageal adenocarcinoma cell lines (ESO26, OE33, ESO51, SK-GT-2, OE19, OACM5.1C
and Flo-1) were obtained from Sigma Aldrich (St. Lois, MO). All cell lines except Flo-1 were cul-
tured in RPMI-1640 medium (Gibco, Grand Island, New York, USA) whereas Flo-1 was cultured
in DMEM medium (Gibco) supplemented with 10% fetal bovine serum (Hyclone), 2 mM Gluta-
Max (Gibco), 100 U/ml penicillin, 100 mg/ml streptomycin at 37˚C in a humidified atmosphere of
95% air– 5% CO2. ESO26, a loosely adherent cell line was established from a primary tumor located
at the gastroesophageal junction and distal esophagus of a 56 year-old Caucasian male, OE33, an
adherent cell line was established from the adenocarcinoma of the lower esophagus with Barrett’s
metaplasia in a 73 year-old Caucasian female, ESO51, a suspension cell line was established from
the distal esophagus with the presence of Barrett’s transformed mucosa in a 74 year-old Caucasian
male, SK-GT-2, an adherent cell line was established from a poorly differentiated primary adenocar-
cinoma of gastric fundus in a 72 year-old Hispanic male, OE19, an adherent cell line was established
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from an adenocarcinoma of the gastric cardia/esophageal gastric junction in a 72 year-old Cauca-
sian male, OACM5.1C, an adherent cell line was established from a lymph node metastasis derived
from primary adenocarcinoma of the distal esophagus with the presence of Barrett’s transformed
mucosa of a 47 year-old Caucasian female and Flo-1, an adherent cell line was established from a
primary esophageal adenocarcinoma in a 68 year-old Caucasian male. Paclitaxel was bought from
Hospira, Inc., Lake Forest IL 60045 and Carboplatin was bought from Sellersville, PA 18960.
Peritoneal-disseminated animal survival model
Four to six week old female non-obese diabetic/severe combined immunedeficient (NOD/
SCID) bought from Charles River were used in this study. All mice were maintained under
pathogen free condition. Mice were intraperitoneally injected with 5X106 to 10X106 cells per
mouse. Peritoneal tumor formation and animal survival were evaluated from the day of cancer
cell injection until death. Animals were examined daily for signs of distress or development of
jaundice and body weight was measured once a week. Animals were euthanized when they
became moribund according to predefined criteria like rapid weight loss (>20%) or weight
gain (>20% due to ascites), loss of ability to ambulate, labored respiration, or inability to drink
or feed to avoid animal suffering [20, 21] in line with the local animal care committee protocol.
After euthanasia animals were examined for the presence and extent of intraabdominal
tumors. The peritoneal tumors and hepatic implants were harvested, immersion-fixed in 4%
formaldehyde and paraffin-embedded. For microscopic examination, 5 μm thick tissue sec-
tions were obtained and stained with hematoxylin and eosin.
Mice survival studies were performed [22] with paclitaxel and carboplatin treatments.
10X106 esophageal adenocarcinoma OE19 cells were intraperitoneally injected in each 4–6
weeks female SCID mouse. Mice were randomly grouped (n = 5 per group) two weeks after
OE19 cells injection. Mice were treated intraperitoneally with vehicle, paclitaxel (20 mg/kg, 2
times a week for 2 weeks) or carboplatin (50 mg/kg, 2 times a week for 2 weeks). Animal sur-
vival was evaluated from the first day of treatment until death. Body weight was measured
twice a week. Animals were euthanized when turning moribund according to above men-
tioned predefined criteria.
Subcutaneous tumor growth model
Female NOD/SCID mice (4 to 6 weeks old) were subcutaneously injected with all seven esoph-
ageal adenocarcinoma cell lines (5X106). Measurements of subcutaneous tumor size were
started when mice had measurable tumors. The tumor size was measured twice a week for
four weeks with with slide calipers and tumor volume (TV) was calculated as (W2XL)/2, where
W is width and L is length of the tumor [23]. Relative tumor volume (RTV) was calculated
according to the following formula; RTV = TVn/TV0 where TVn is the tumor volume at the
day of measurement and TV0 is the tumor volume on the first day of measurement [24].
Subsequent subcutaneous tumor growth study was performed where OE19 (5X106) cells
were subcutaneously injected in female NOD/SCID mice. All mice had measurable tumor two
weeks after OE19 cell injection. The mice were then randomly grouped (n = 5 per group) and
treated intraperitoneally as described earlier with vehicle, paclitaxel (20 mg/kg, 2 times a week
for 2 weeks) [25] or carboplatin (50 mg/kg, 2 times a week for 2 weeks) [26]. Subcutaneous
tumor size was measured twice a week for two weeks and TV with RTV was calculated as
described earlier. Mice weight was measured twice a week during the period of the study. All
mice were euthanized at the end of study.
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Cell viability assay
Cell viability of esophageal adenocarcinoma OE19 cell line was evaluated by the colorimetric
WST-1 assay as previously described [27]. The measurement is based on the ability of viable
cells to cleave the sulfonated tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio]-1,3-benzene disulfonate) by mitochondrial dehydrogenases. OE19 cell (4,000
cells/well) were plated in a 96-well plate in regular growth medium. After 16 hours the
medium was replaced with 2% FBS containing medium and the cells were treated with pacli-
taxel or carboplatin (1 nM to 5 μM). After 72 hours, 10 μL WST-1 reagent was added in each
well followed by additional incubation for 2 hours. The absorbance at 450 nm was measured
using a microplate reader.
Statistical analysis
The comparison of survival time between different groups was done by using the log-rank test,
which is implemented in the "survdiff" function in the R [28] package "survival" [29, 30]. The
comparison of the relative tumor volume (RTV) between treatment groups was done by first
normalizing the RTV values at day 14 by the mean TRV value of the corresponding group at
day 0, and then applying the two-sample t test, implemented in the "t.test" R function. p<0.05
was considered statistically significant.
Results
Establishment of a mouse model for peritoneal metastasis of EAC
To find the best candidate cell line for the establishment of a mouse model of peritoneal dis-
seminated EAC we used seven EAC cell lines of various origin (Table 1).
All seven EAC cell lines except OACM5.1 C formed intraperitoneal tumors at variable rates
(Table 2).
No peritoneal tumor was observed in mice injected with OACM5.1C even at 4 months
(Figs 1A, 2A and 2B). After intraperitoneal injection of 5X106 EAC cells in SCID mice earliest
multiple peritoneal tumor formation was observed in the OE19 model, followed by the OE33
and the SK-GT-2 models (Fig 1B, 1C and 1D). Interestingly, only in the OE19 model all mice
(7/7 for 5X106 and 5/5 for10X106) (Table 2) had bloody ascites (Figs 1B, 2C and 2D) with liver
metastasis/implants (Fig 3) after intraperitoneal injection of cells. Bloody ascites within 2
months was observed in the OE19 (100% cases) and the OE33 (50% cases) models (Table 2).
Especially with the OE19 injected mice, the ascites was almost entirely blood and there were
very distinct cell aggregates within the ascetic fluid. Invasion of the omentum, the body wall
and the diaphragm was also observed especially in the OE19 models.
Table 1. Cell lines used to establish peritoneal dissemination xenograft mouse model of esophageal
adenocarcinoma.
Cell lines name Cell lines origin
OE19 Adenocarcinoma of the gastroesophageal junction and gastric cardia (Caucasian)
OE33 Adenocarcinoma of the lower esophagus (Barrett’s metaplasia)
(Caucasian)
ESO26 Adenocarcinoma of the gastroesophageal junction and distal esophagus (Caucasian)
Flo-1 Adenocarcinoma of the distal esophagus (Caucasian)
SK-GT-2 Adenocarcinoma of the gastric fundus (Hispanic male), poorly differentiated
ESO51 Adenocarcinoma of the distal esophagus (Caucasian) (Barrett’s metaplasia)
OACM5.1C Adenocarcinoma of the distal esophagus (Caucasian)
doi:10.1371/journal.pone.0171824.t001
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Animal survival in the peritoneal disseminated model
The longevity of the mice after intraperitoneal injection of EAC cell lines served as an indicator
of the aggressiveness and tumorigenicity of the injected cells. Median survival time for each
cell line is recorded in Table 2. Median animal survival with peritoneal dissemination was 108
days for ESO26 cells (5X106), 65 days for OE33 cells (5X106), 88 days for ESO51 cells (5X106),
76 days for SK-GT-2 cells (5X106), 55 days for OE19 cells (5X106), 45 days for OE19 cells
(10X106) and 82 days for Flo-1 cells (5X106). The most aggressive cell line OE19 resulted in a
median survival time of less than 60 days. We therefore further characterized the animal sur-
vival in the OE19 model with more mice using variable numbers of OE19 cells (5X106
and10X106). We observed a very good animal survival time frame (45 days for 10X106) for
possible therapeutic interventions in an animal survival study.
Effect of anticancer drugs on animal survival
We chose the OE19 SCID mouse peritoneal disseminated model for the evaluation of thera-
peutic interventions. In this model, the animals were treated with anticancer drugs over a
period of 14 days, starting 14 days after intraperitoneal injection of OE19 cells (10X106). The
median survival was 46 days in the control (vehicle) group. The median survival of mice was
increased by paclitaxel treatment to 57 days (p = 0.0034, control versus paclitaxel) and also by
carboplatin treatment to 53 days (p = 0.0034, control versus carboplatin); the p-value is exactly
the same as control versus paclitaxel, since the log-rank test is a nonparametric test (Fig 4).
Table 2. Metastasis and survival outcome after intraperitoneal (IP) inoculation of esophageal adenocarcinoma cell lines.
Esophageal adenocarcinoma
cell lines
Number of injected
cells (IP)
Total number of
mice used
Rate of colonization of
peritoneum
Rate of bloody
ascites
Median survival
(Days)
OE19 5X106 2+5 = 7 7/7 7/7 55
OE19 10X106 5 5/5 5/5 45
OE33 5X106 2 2/2 1/2 65
ESO26 5X106 2 2/2 0/2 108
Flo-1 5X106 2 2/2 1/2 82
SK-GT-2 5X106 2 2/2 1/2 76
ESO51 5X106 2 2/2 0/2 88
OACM5.1C 5X106 2 0/2 0/2 >120
doi:10.1371/journal.pone.0171824.t002
Fig 1. Formation of peritoneal tumor nodules and bloody ascites in SCID mice after intraperitoneal
injection of 5X106 cells. (A) No peritoneal tumor formation was observed even 4 months (120 days) after
intraperitoneal injection of OACM5.1C cells. (B) Multiple peritoneal tumor formation with bloody ascites was
observed ~55 days after intraperitoneal injection of OE19 cells. (C) Multiple peritoneal tumor formation but no
bloody ascites was observed in OE33 cells ~65 days after intraperitoneal injection. (D) Similarly in SK-GT-2
cells multiple peritoneal tumor formation without bloody ascites was observed ~76 days after intraperitoneal
injection. Blue arrows show the tumors.
doi:10.1371/journal.pone.0171824.g001
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The difference in survival between the two treatments are also statistically significant, with
p = 0.018.
Subcutaneous tumor growth and effect of anticancer drugs
All cell lines injected subcutaneously formed tumors within 3 months at variable rates (Fig
5A). Accelerated subcutaneous tumor growth was observed in the OE19 EAC cell line indicat-
ing its high tumorigenicity with aggressive phenotype in the animal model. Similar to the sur-
vival model, the OE19 subcutaneous tumor model showed therapeutic response to paclitaxel
and carboplatin treatments (Fig 5B). The relative tumor volume (RTV) was decreased by
60.77% with paclitaxel (p = 0.00011) treatment and 34.34% with carboplatin (p = 0.0075) treat-
ment. There was no significant decrease in animal weight in therapeutic groups (Fig 5C).
Higher in vitro antiproliferative potency of paclitaxel over carboplatin on
OE19 cells
We compared controls with two different treatments, paclitaxel and carboplatin, under differ-
ent concentrations (1 nM, 10 nM, 50 nM, 250 nM, 1000 nM, and 5000 nM). We had four
Fig 2. Ascites in SCID mice after intraperitoneal injection of 5X106 cells. (A) & (B) There was no ascites
observed in OACM5.1C cells. (C) & (D) Ascites was observed in OE19 cells.
doi:10.1371/journal.pone.0171824.g002
Fig 3. Peritoneal and hepatic tumor xenograft formation after intraperitoneal injection of OE19 cells.
(A) Peritoneal tumor implant in SCID mice. (B) Low & (C) high power H&E stained sections of peritoneal
tumors. (D) Hepatic tumor implants (blue arrows). (E) H&E staining of hepatic tumor implant (blue arrows). (F)
H&E staining of OE19 metastasis to liver (blue arrows).
doi:10.1371/journal.pone.0171824.g003
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Fig 4. Mice survival in the OE19 peritoneal dissemination model treated with carboplatin and
paclitaxel. 10X106 OE19 cells were injected intraperitoneally in SCID mice and treatment started after 2
weeks and continued for another 2 weeks. The curve represents the animal survival time from the day of
implantation. * Represents significant differences compared with control (vehicle) at p = 0.0034.
doi:10.1371/journal.pone.0171824.g004
Fig 5. Study of subcutaneous tumor growth with changes of relative local tumor volume (RTV) and
mouse weight after paclitaxel and carboplatin treatments in the OE19 subcutaneous mouse model.
(A) Relative tumor volumes over a period of 4 weeks after subcutaneous injection of 5X106 cells of seven
esophageal adenocarcinoma cell lines. Enhanced relative tumor volumes were observed in OE33, OE19,
ESO26 and SK-GT-2 cell lines. (B) RTV changes after paclitaxel and carboplatin treatments compared to
control (vehicle) in OE19 subcutaneous mouse model. * indicates p<0.05 versus control. (C) No significant
body weight change was observed after paclitaxel and carboplatin treatments compared to control in the
OE19 subcutaneous mouse model.
doi:10.1371/journal.pone.0171824.g005
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replicates in the control group, and in each concentration. First, we computed the proportion
of cells surviving after each concentration, which was calculated by
proportion ¼ 1  
measurement under a concentration
mean measurement under control
:
These proportions are shown as scatter plots in the Fig 6. The proportions from the pacli-
taxel treatment are shown as red points, and the proportions from the carboplatin treatment
are shown as blue points. We log-transformed the concentrations to match our experimental
design. It is clear that the relationship between proportions and log-concentrations are not lin-
ear. To reflect this, we fit a natural cubic spline [31] instead of a linear regression. The fitted
splines are shown as red and blue lines for the two treatments. The log(IC50) values are 7.729
and 10.328, respectively. That is, the IC50 value is 2273 for the paclitaxel treatment, and 30577
for the carboplatin treatment. We saw that the IC50 value for the carboplatin treatment is
about 13.45 times of the IC50 value for the paclitaxel treatment. To check whether this differ-
ence is statistically significant, we used the bootstrap to test the null hypothesis: IC50 of the
two treatments are the same, versus the alternative hypothesis: IC50 of the carboplatin treat-
ment is larger than the paclitaxel treatment. Based on ten thousand bootstrap resamplings, we
get p-value = 0.0040, giving very strong evidence in rejecting the null hypothesis.
Fig 6. Higher antiproliferative potency of paclitaxel over carboplatin. OE19 cells were plated on 96-well
plate and treated with 1 nM to 5000 nM concentrations of paclitaxel (red points) or carboplatin (blue points).
After 72 hours, 10 μl WST-1 reagent was added in each well and incubated for 2 additional hours. The
absorbance at 450 nm was measured using a microplate reader. The resulting number of viable cells was
calculated by measuring absorbance of color produced in each well. Data are the mean ± SD of quadruplet
doi:10.1371/journal.pone.0171824.g006
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Discussion
Establishment of subcutaneous and orthotopic esophageal adenocarcinoma (EAC) xenograft
models has been reported previously [13, 18, 32–35]. However, there is no report of an EAC
animal survival model after intraperitoneal injection of EAC cells. In this study, we established
a novel animal model of peritoneal metastasis of EAC and evaluated the efficacy of most com-
monly used anticancer drugs for EAC therapy on animal survival. This study has important
findings relevant to the development of new EAC survival models which will benefit EAC
basic-research and preclinical drug-testing.
First, we succeeded in a reliable manner in establishing an EAC animal model of peritoneal
metastasis in which peritoneal colonization of EAC cells occurred. To screen the best candidate
cell line for this model, we used seven EAC cell lines in an attempt to establish a peritoneal dis-
semination model. After intraperitoneal injection of 5X106 cells all cell lines except OACM5.1 C
led to the development of peritoneal disseminated tumors in SCID mice at different time points.
Among all these seven cell lines the earliest peritoneal tumor formation with shortest survival
time was observed in the OE19 model. In addition, only in the OE19 model we persistently
observed bloody ascites with liver metastasis. Regional lymph node metastasis has been observed
by others after orthotropic injection of OE19 cells [32, 33]. Thus it seemed that the OE19 cell line
was the best choice for a peritoneal metastatic model. We are therefore reporting the use of the
OE19 cells for studying the survival outcome after peritoneal metastasis and consider it a useful
model for examining new investigational therapeutic targets and agents for EAC. Our mouse
survival model does not require any surgical procedure and is very simple to perform. Thus it is
not only reliable and reproducible but also has a high degree of feasibility and is user friendly.
Secondly, we succeeded to observe a survival benefit in this OE19 model after treatment with
clinically-proven anticancer drugs [36–38]. The main treatment for inoperable and metastatic
EAC is systemic chemotherapy. Various anticancer drugs including paclitaxel and carboplatin
have been used in recent years for treating patients with EAC [37]. However, severe side effects
of using high dose or combination anticancer chemotherapeutics have limited their application.
Therefore, new anticancer drugs including molecularly targeted agents must be developed. In
our mouse survival model the median survival after intraperitoneal injection of 10X106 OE19
cells was 46 days. This time frame is optimal for investigational therapeutic interventions with
novel anticancer drugs with a sufficient duration to expect outcome differences. In our animal
survival model, animal survival was significantly improved by paclitaxel and carboplatin injec-
tions, the standard anticancer agents frequently used clinically in EAC therapy.
Subcutaneous implantation xenograft and orthotropic models have been previously used
for in-vivo experiments using EAC human cell lines for anticancer drug evaluation [14, 18, 32,
33, 39]. However, subcutaneous implantation models rarely metastasize and are not patient-
like. In contrast, orthotropic models resemble human EAC disease progression more closely
and frequently metastasize. Therefore they are considered to be the better option for studying
EAC than the subcutaneous models. However, the establishment of an EAC orthotropic
model is extremely difficult and is technically challenging to reproduce due to the anatomical
location and small size of the mouse esophagus. In addition, it requires invasive procedures
which can induce inflammation and thus may influence the efficacy of subsequent therapeutic
interventions. Low invasiveness and cost effectiveness are some of the most important points
for the ideal animal experiment. Accurate animal studies should be assessed with the least
amount of outside influence possible. Thus, a simple, least invasive, patient-like EAC survival
model with similar metastatic behavior has been needed.
Injection of cancer cells in the tail vein to implant cells in the lung and thus produce lung
tumors is commonly used to study murine model of cancer lung metastasis [40, 41]. As EAC
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often metastasizes to the lung, tail vein injection can be employed to produce a survival model
of EAC with lung metastasis. However, it has the disadvantages of formation of no lung
tumors but instead only cancer cell colonization and of lacking the step of progression of the
primary tumor to metastasis [40]. Our preliminary experiments with tail vein injection of
OE19 cells also found cancer cell colonization with no lung tumor formation and failed to
demonstrate a favorable time frame for survival outcome assessment. In addition, adenocarci-
noma of the gastroesophageal junction commonly metastasizes to the peritoneal cavity and
liver. Our OE19 survival model of diffuse peritoneal tumors with hepatic metastasis showed an
optimal time frame to study the therapeutic response of metastasis. Thus, we have succeeded
to produce patient-like tumor colonization of the peritoneal cavity and hepatic metastasis with
the human EAC cell line OE19 by intraperitoneal injection in SCID mice. We used SCID mice
over nude mice for the metastatic survival model because the survival effects were more repro-
ducibly obtained in SCID mice than in nude mice. It took only 2 weeks at the earliest after
intraperitoneal injection of OE19 to confirm metastatic nodules macroscopically. That is why
we chose this time point to start treatment with our anticancer chemotherapeutics. Macro-
scopic metastatic nodules formation occurred for other EAC cell lines except OACM5.1C at
later time points.
In summary, we were able to develop a reproducible, dependable and workable SCID
mouse EAC peritoneal dissemination survival model with intraperitoneal injection of 10X106
OE19 cells. Paclitaxel and carboplatin treatment showed efficacy both in local subcutaneous
tumor growth and survival outcomes. This finding supports the novel and useful model for
survival outcome analysis in EAC therapy research.
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